p35/25 (C64B10) Rabbit mAb





Orders:	877-616-CELL (2355 orders@cellsignal.com			
Support:	877-678-TECH (8324			
Web:	info@cellsignal.com cellsignal.com			

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP, IHC-P, IF-F	Reactivity: H M R	Sensitivity: Endogenous	MW (kDa): 25, 35	Source/Isotype: Rabbit	UniProt ID: #Q15078	Entrez-Gene Id: 8851		
Product Usage Information		Application Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence (y (Paraffin) Frozen)		Dil 1:1 1:5 1:5 1:1	lution 1000 50 50 100		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
		For a carrier free (BSA and azide free) version of this product see product #52675.						
Specificity/Sens	itivity	p35/25 (C64B10) Rabbit mAb detects endogenous levels of total p35 protein. The antibody also detects endogenous p25 resulting from calpain-mediated cleavage upon neurotoxic insult.						
Source / Purifica	rce / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide from the caterinius of human p35.		om the carboxy					
Background		Cyclin-dependent kinases (CDKs) are serine/threonine kinases that are activated by cyclins and gover eukaryotic cell cycle progression. While CDK5 shares high sequence homology with its family member it is thought mainly to function in postmitotic neurons, regulating the cytoarchitecture of these cells. Analogous to cyclins, p35 and p39 associate with and activate CDK5 despite the lack of sequence homology. CDK5 is ubiquitously expressed, but high levels of kinase activity are detected primarily in the nervous system due to the narrow expression pattern of p35 and p39 in post-mitotic neurons. A large number of CDK5 substrates have been identified although no discrete substrates have been attributed as a function of p35 vs. p39. Amongst many, substrates of CDK5 include p35 and p39. p35 rapidly degraded (T1/2 <20 min) by the ubiquitin-proteasome pathway (1). However, p35 stability increases as CDK5 kinase activity decreases, and this is likely a result of decreased phosphorylation o p35 at Thr138 by CDK5 (2). NGF activates Erk and EGR1, and induces p35 expression in PC12 cells (3). Proteolytic cleavage of p35 by calpain produces p25 upon neurotoxic insult, resulting in prolonged activation of CDK5 by p25. Accumulation of p25 is found in neurodegenerative diseases such as Alzheimer's disease and Amvotrophic Lateral Sclerosis (ALS) (4-5).						
Background Ref	erences	1. Dhavan, R. and Tsai, L.H. (2001) <i>Nat. Rev. Mol. Cell Biol.</i> 2, 749-759. 2. Patrick, G.N. et al. (1998) <i>J. Biol. Chem.</i> 273, 24057-24064. 3. Harada, T. et al. (2001) <i>Nat. Cell Biol.</i> 3, 453-459. 4. Lee, M.S. et al. (2000) <i>Nature</i> 405, 360-364. 5. Kusakawa, G. et al. (2000) <i>J. Biol. Chem.</i> 275, 17166-17172.						
Species Reactivi	ty	Species reactivity is det	termined by testing	g in at least one approve	d application (e.g.,	western blot).		
Western Blot Bu	Iffer	IMPORTANT: For weste TBS, 0.1% Tween® 20 a	ern blots, incubate at 4°C with gentle s	nembrane with diluted primary antibody in 5% w/v BSA, 1X aaking, overnight.				
Applications Key	y	W: Western Blotting IP Immunofluorescence (l	: Immunoprecipita Frozen)	precipitation IHC-P: Immunohistochemistry (Paraffin) IF-F:				
Cross-Reactivity	' Key	H: Human M: Mouse R: Rat						
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		U.S. Patent No. 7.429.4	87, foreign equival	ents, and child patents o	leriving therefrom.			

All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party. whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.